The Hematology Billing Cycle
Hematology billing is more complex than most medical specialties because it involves three distinct revenue streams that must be managed simultaneously: cognitive E/M services (office visits for diagnosis, monitoring, and treatment planning), drug administration services (chemotherapy infusion, injection, and transfusion), and drug buy-and-bill (purchasing drugs at acquisition cost and billing payers at contracted or ASP-based rates). Each stream has its own coding rules, documentation requirements, and revenue cycle considerations. The administration and drug streams are tightly linked because an error in administration coding can cascade into a drug payment denial.
Step 1: Pre-Treatment Authorization and Drug Verification
Before administering chemotherapy or biologic agents, obtain prior authorization from the payer. Hematology drugs are among the most expensive in medicine (some costing $10,000+ per dose), and payers require authorization for virtually all chemotherapy regimens. The authorization must specify the drug name, dose, schedule (number of cycles), and diagnosis. Verify that the authorized drug matches the prescribed regimen. If the regimen changes (dose adjustment, drug substitution due to adverse reaction), obtain a revised authorization before administering the new drug. Simultaneously, verify the patient insurance coverage, copay assistance program enrollment, and any specialty pharmacy requirements.
Step 2: Infusion Session Documentation
During the infusion session, clinical staff must document: patient arrival time, vital signs before treatment, drug name(s), dose(s), route of administration (IV infusion, IV push, subcutaneous, intramuscular), infusion start and stop times for each drug, hydration start and stop times, any pre-medications administered (anti-emetics, steroids, diphenhydramine), adverse reactions and interventions, and vital signs after treatment. The infusion start and stop times directly determine the CPT administration codes because the time thresholds define the code selection. A chemotherapy infusion that runs for 55 minutes qualifies for 96413 (first hour). An infusion running 65 minutes qualifies for 96413 plus 96415 if the additional time exceeds 30 minutes beyond the first hour.
Step 3: Administration Code Assignment
Assign administration codes based on the documented infusion timeline. Follow the hierarchy: chemotherapy infusion (96413-96417) takes precedence over non-chemotherapy infusion (96365-96368), which takes precedence over therapeutic injection (96401-96402), which takes precedence over hydration (96360-96361). For each drug administered, determine: the route (infusion, push, injection), the duration, and the position in the sequence. The first chemotherapy infusion of the session uses 96413. If it runs over 1 hour, add 96415 for each additional hour (31+ minutes beyond the previous hour). The second chemotherapy drug infused sequentially uses 96417. IV push drugs use 96409 (first push) and 96411 (each additional).
Step 4: Drug Billing (J-Codes)
Bill the drug using the appropriate HCPCS J-code (or C-code for hospital outpatient settings). The J-code identifies the drug and the billing unit. For example, J9035 (bevacizumab) is billed per 10 mg. A 500 mg dose requires 50 units of J9035. Calculate the number of billing units carefully because rounding errors create overpayment (compliance risk) or underpayment (revenue loss). Bill the drug on the same claim as the administration code, linked to the same diagnosis code. The drug reimbursement for Medicare is based on the Average Sales Price (ASP) plus a percentage markup (currently ASP + 6%). Commercial payer drug reimbursement varies by contract but is typically based on ASP or AWP (Average Wholesale Price) with a discount.
Step 5: Claim Submission with Treatment Documentation
Submit claims within 48 hours of the treatment date. Include the administration CPT codes, drug J-codes with correct unit quantities, E/M code if a separately identifiable visit occurred on the treatment date (with modifier 25), diagnosis codes supporting both the disease and the treatment (C91.10 for CLL as the disease, Z51.11 for encounter for antineoplastic chemotherapy as the treatment reason), and the prior authorization number. For multi-drug regimens, ensure that every drug on the treatment plan has a corresponding J-code and administration code on the claim. Missing any component results in partial payment or denial.
Step 6: Drug Inventory and Financial Reconciliation
Reconcile drug inventory monthly. Track the acquisition cost of each drug purchased, the number of units administered to patients, the number of units billed to payers, and the reimbursement received. The drug margin (reimbursement minus acquisition cost) should be positive for the practice to sustain the buy-and-bill model. If a specific drug margin turns negative (acquisition cost exceeds reimbursement), evaluate whether to continue buying and billing the drug or transition to a specialty pharmacy model where the pharmacy ships the drug and bills the payer directly. Track drug wastage (unused portions of single-dose vials) using the JW modifier and bill for wasted drug when payer policy allows.